Bavarian Nordic A/S ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.62
- Today's High:
- $6.655
- Open Price:
- $6.62
- 52W Low:
- $8.34
- 52W High:
- $19.31
- Prev. Close:
- $6.655
- Volume:
- 2387
Company Statistics
- Market Cap.:
- $2.24 billion
- Book Value:
- 41.1568
- Revenue TTM:
- $4.08 billion
- Operating Margin TTM:
- 12.03%
- Gross Profit TTM:
- $1.70 billion
- Profit Margin:
- 7.37%
- Return on Assets TTM:
- 2.44%
- Return on Equity TTM:
- 3.7%
Company Profile
Bavarian Nordic A/S ADR had its IPO on under the ticker symbol BVNRY.
The company operates in the Healthcare sector and Biotechnology industry. Bavarian Nordic A/S ADR has a staff strength of 1,040 employees.
Stock update
Shares of Bavarian Nordic A/S ADR opened at $6.62 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.62 - $6.66, and closed at $6.64.
This is a -0.23% slip from the previous day's closing price.
A total volume of 2,387 shares were traded at the close of the day’s session.
In the last one week, shares of Bavarian Nordic A/S ADR have slipped by -10.63%.
Bavarian Nordic A/S ADR's Key Ratios
Bavarian Nordic A/S ADR has a market cap of $2.24 billion, indicating a price to book ratio of 2.198 and a price to sales ratio of 0.9318.
In the last 12-months Bavarian Nordic A/S ADR’s revenue was $4.08 billion with a gross profit of $1.70 billion and an EBITDA of $859.46 million. The EBITDA ratio measures Bavarian Nordic A/S ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bavarian Nordic A/S ADR’s operating margin was 12.03% while its return on assets stood at 2.44% with a return of equity of 3.7%.
In Q1, Bavarian Nordic A/S ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 291.2%.
Bavarian Nordic A/S ADR’s PE and PEG Ratio
- Forward PE
- 4.99
- Trailing PE
- 47.75
- PEG
- 0
Its diluted EPS in the last 12-months stands at $0.2 per share while it has a forward price to earnings multiple of 4.99 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bavarian Nordic A/S ADR’s profitability.
Bavarian Nordic A/S ADR stock is trading at a EV to sales ratio of 0.8119 and a EV to EBITDA ratio of -62.0539. Its price to sales ratio in the trailing 12-months stood at 0.9318.
Bavarian Nordic A/S ADR stock pays annual dividends of $0 per share, indicating a yield of 3.75% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $13.18 billion
- Total Liabilities
- $1.79 billion
- Operating Cash Flow
- $0
- Capital Expenditure
- $242.86 million
- Dividend Payout Ratio
- 0%
Bavarian Nordic A/S ADR ended 2024 with $13.18 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $13.18 billion while shareholder equity stood at $9.12 billion.
Bavarian Nordic A/S ADR ended 2024 with $0 in deferred long-term liabilities, $1.79 billion in other current liabilities, 778730000.00 in common stock, $8.23 billion in retained earnings and $0 in goodwill. Its cash balance stood at $1.27 billion and cash and short-term investments were $2.97 billion. The company’s total short-term debt was $25,758,000 while long-term debt stood at $662.95 million.
Bavarian Nordic A/S ADR’s total current assets stands at $5.12 billion while long-term investments were $0 and short-term investments were $1.70 billion. Its net receivables were $741.36 million compared to accounts payable of $444.83 million and inventory worth $1.20 billion.
In 2024, Bavarian Nordic A/S ADR's operating cash flow was $0 while its capital expenditure stood at $242.86 million.
Comparatively, Bavarian Nordic A/S ADR paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $6.64
- 52-Week High
- $19.31
- 52-Week Low
- $8.34
- Analyst Target Price
- $
Bavarian Nordic A/S ADR stock is currently trading at $6.64 per share. It touched a 52-week high of $19.31 and a 52-week low of $19.31. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $7.89 and 200-day moving average was $9.53 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Bavarian Nordic A/S ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.